ADVAC Therapeutics Inc — SEC Form D Filing

ADVAC Therapeutics Inc filed an SEC Form D on March 10, 2026, reporting $500K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
March 10, 2026
Amount reported
$500K
Industry
Pharmaceuticals
Website
https://advactherapeutics.ozcorp.io/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Current therapies do not exist to stimulate the regrowth of healthy lung tissue following infections such as pneumonia.

Solution

Advac Therapeutics is developing a novel therapy that aims to regenerate damaged lung tissue by mimicking natural healing mechanisms of the lungs.

Why now

There is a critical need for effective treatments for lung regeneration as pneumonia remains a leading cause of death in vulnerable populations.

Verdict

Investors supported ADVAC Therapeutics at this moment due to the urgent unmet need for therapies that regenerate lung tissue, implicitly betting on the therapeutic efficacy of a novel solution in a critical health landscape. This cleared because the promise of addressing a significant healthcare gap resonated, not because of established market traction or a defined competitive edge. However, the limited upside stems from the inherent risks in therapeutic development and the challenge of navigating regulatory hurdles in pharmaceuticals.

Source: SEC EDGAR Form D filing